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group had an index of 0.06  0.01, the diabetic group wasCyclooxygenase-2 inhibitor blocks expression of mediators of
2.7  0.04 and the treated group was 0.6  0.03 (P  0.0001renal injury in a model of diabetes and hypertension.
compared to the diabetic group).Background. We previously reported that renal cortical
Conclusions. These results suggest that in an experimentalcyclooxygenase (COX-2) expression increased following subto-
model of diabetes and hypertension, inhibition of COX-2 ex-tal nephrectomy, and chronic treatment with a selective COX-2
inhibitor, SC58236, reduced proteinuria and retarded the de- pression decreases potential mediators of glomerular and tubu-
velopment of glomerulosclerosis. The present studies were de- lointerstitial injury and also decreases biochemical, functional
signed to examine the effects of COX-2 inhibition in a model and structural markers of renal injury.
of diabetic nephropathy.
Methods. Rats were divided into three groups: control, dia-
betic (streptozotocin-induced diabetic animals with superim-
Previous studies have suggested that prostaglandinsposed DOCA/salt hypertension; right nephrectomy and DOCA
treatment), and treated (administration of the selective COX-2 may be involved in the development of diabetic nephrop-
inhibitor, SC58236, to a subset of diabetic/DOCA/salt rats). athy. Increased urinary and glomerular prostaglandin
Insulin was administered to maintain blood glucose in the 200 production has been reported in experimental models
to 300 mg/dL range.
of diabetes [1–5]. Prostaglandins have been implicatedResults. Systolic blood pressure in the two diabetic groups
as mediators of the alterations in renal hemodynamicswas elevated within one week and remained elevated until
sacrifice at six weeks (control, 108 2 mm Hg; diabetic, 158 in early diabetes [3, 6, 7], and of increased mesangial
4 mm Hg; treated, 156  7 mm Hg). When measured at six cell proliferation and matrix accumulation [6, 8, 9].
weeks, immunoreactive COX-2 expression in the renal cortex Prostaglandins arise from enzymatic metabolism ofof the diabetic rats was 2.5  0.3-fold of control animals (N 
arachidonic acid by prostaglandin G2/H2 synthase (cyclo-7). Immunohistochemical localization indicated increased ex-
oxygenase) and further metabolism by specific synthasespression in macula densa and surrounding cortical thick as-
cending limb of Henle (cTALH). The COX-2 inhibitor de- [10]. There are two isoforms of cyclooxygenase: cyclo-
creased COX-2 expression in diabetic rats to 1.3  0.1-fold oxygenase-1 (COX-1), the constitutive enzyme [11], and
control. In addition, SC58236 decreased expression of PAI-1 cyclooxygenase-2 (COX-2), the inducible enzyme [12].(diabetic vs. treated, 3.2  0.5 vs. 1.7  0.2-fold control, N 
In response to gastrointestinal side effects induced by7, P  0.05), vascular endothelial growth factor (VEGF; 2.0 
non-steroidal anti-inflammatory drugs (NSAIDs), whose0.2 vs. 1.2  0.2; N  7, P  0.05), fibronectin (2.4  0.3 to
1.3  0.1; N  7, P  0.05) and transforming growth factor- mechanism of action involves competitive or non-com-
(TGF-; 2.1  0.2 vs. 1.3  0.2; N  7, P  0.05). Proteinuria petitive inhibition of both COX-1 and COX-2 activity,
at six weeks was decreased in the SC58236-treated rats (149  the pharmaceutical industry has recently developed se-8 vs. 92 8 mg/24 h; N 7, P 0.01). The mesangial sclerosis
lective COX-2 antagonists. Our previous studies haveindex, defined as increases in extracellular matrix within the
indicated that the normal adult rat kidney has low butmesangial space, was determined at six weeks; the control
measurable levels of COX-2 expression, which is local-
ized to scattered cortical thick ascending limb cells and
1 See Editorial by Zatz and Fujihara, p. 1091. macula densa cells and to a subset of medullary intersti-
tial cells in the papilla [13]. In chronically salt depletedKey words: SC58236, prostaglandins, diabetic nephropathy, macula
densa, TGF-, PAI-1, VEGF, tubulointerstitial injury, glomerular injury. animals, COX-2 expression in the peri-macula densa re-
gion increases significantly [13]. In addition, we and oth-
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a selective inhibitor of COX-2 retarded progression of ples were collected weekly and measured by the BCA
protein assay reagent kit (Pierce).glomerular sclerosis after subtotal ablation [16]. The goal
of the present studies was to determine the effects of
Morphologic assessmentchronic treatment with a COX-2 inhibitor upon an exper-
imental model of moderately controlled diabetes with At the end of six weeks, animals were sacrificed and
kidneys were weighed, then fixed in 10% formalin, em-superimposed hypertension.
bedded with paraffin and 4 m slides were cut and
stained with hematoxylin and eosin (H&E), periodic
METHODS
acid-Schiff (PAS) and Jones stains. Mesangial sclerosis
Materials was defined as the increase in extracellular matrix within
the mesangial space. The mesangial sclerosis index wasSprague-Dawley rats were from Harlan (Indianapolis,
IN, USA). The selective COX-2 inhibitor, SC58236, scored on Jones stained slides by averaging scores for
all glomeruli on a slide (100 glomeruli are typicallywhich exhibits a COX-2/COX-1 selectivity of 1780-fold
[17], was a gift from Searle Monsanto Co. (St. Louis, MO, present on kidney sections obtained at autopsy of the
rats): 0  normal, 1  up to 30% sclerosis, 2  31 toUSA). Rabbit anti-COX-2 antibody was from Cayman
Chemical Co. (Ann Arbor, MI, USA), goat anti-COX-2 60% sclerosis, 3  61 to 90% sclerosis and 4  90%
sclerosis. Tubulointerstitial fibrosis was assessed onantibody, rabbit anti-VEGF and anti-PAI-1 antibodies
were from Santa Cruz Biotechnology (Santa Cruz, CA, Jones stained slides by scoring all high power fields in a
similar semiquantitative manner with 1  up to 30% ofUSA), goat anti-fibronectin antibody was from Sigma
Chemical Co. (St. Louis, MO, USA) and rabbit anti-TGF- the field involved with fibrosis, 2  31 to 60% fibrosis,
3  61 to 90% involvement and 4  90% fibrosis.was from R&D Laboratory (Minneapolis, MN, USA).
ECL (Enhanced Chemiluminescence Kit) and ECL Hy-
Immunoblottingperfilm were from Amersham (Arlington Heights, IL,
USA). BCA protein Assay Reagent kit, Immunopure For COX-2, renal cortices were homogenized in 30
mmol/L Tris-HCl, pH 8.0, 100 mol/L phenylmethylsul-ABC peroxidase staining kit, and biotin labeled mouse
anti rabbit or rabbit anti goat IgG(HL) antibodies were fonyl fluoride (PMSF; 1:9 wt/vol). Following a 10 minute
centrifugation at 10,000  g, the supernatant was centri-from Pierce (Rockford, IL, USA). Other reagents were
purchased from Sigma Chemical Co. fuged for 60 minutes at 110,000  g to prepare micro-
somes, as described previously [13]. Proteins were resus-
Animal model pended in sodium dodecyl sulfate (SDS) sample buffer.
For detection of other proteins, renal cortices were ho-Male Sprague-Dawley rats, initially weighing 150 to
200 g, were utilized for the diabetic-hypertensive model mogenized with RIPA buffer and centrifuged, heated to
100	C for five minutes with sample buffer, separated onor as normal controls. Animals were anesthetized with
ketamine:xyline (9:1), placed on a warming table and SDS gels under reducing conditions and transferred to
Immobilon-P transfer membranes (Milipore, Bedford,injected with streptozotocin in 0.01 mol/L citrate buffer
(pH 4.5) or normal saline (control) intravenously, as MA, USA). The blots were blocked overnight with 100
mmol/L Tris-HCl, pH 7.4, containing 5% non-fat drypreviously described [60 mg/kg body weight (BW)] [18].
In the animals injected with streptozotocin, a right ne- milk, 3% albumin and 0.5% Tween-20, followed by incu-
bation for 16 hours with polyclonal rabbit COX-2 anti-phrectomy was performed under aseptic condition via a
dorsal lumbotomy incision. One gram deoxycorticoster- serum or other indicated antibodies. The second biotinyl-
ated antibody reagent was detected using avidin andone acetate (DOCA)/kg BW was embedded subcutane-
ously. Only animals that had documented hyperglycemia biotinylated horseradish peroxidase (Pierce) and ex-
posed on film using ECL (Amersham).24 hours after injection were used and were further di-
vided into two experimental groups: the diabetic group
Immunohistochemistrywas administered 1% NaCl, 0.5% PEG200 and 0.025%
Tween 20 (vol/vol) in the drinking water, and the treated Under deep anesthesia with Nembutal (70 mg/kg IP),
rats were exsanguinated with 50 mL/100 g heparinizedgroup received in addition, 0.015 mg/mL SC58236. All
diabetic animals received daily injections of ultralente saline (0.9% NaCl, 2 U/mL heparin, 0.02% sodium ni-
trite) through a transcardial aortic cannula and fixed withinsulin (1-2 U/100 g BW) to maintain blood sugars in
the 200 to 300 mg% range. glutaraldehyde-periodate acid saline (GPAS) for COX-2
and VEGF staining as previously described. GPAS con-
Clinical parameters tains final concentrations of 2.5% glutaraldehyde, 0.011
mol/L sodium metaperiodate, 0.04 mol/L sodium phos-Systolic blood pressure (BP) was measured weekly
with a tail-cuff microphonic manometer, as previously phate, 1% acetic acid and 0.1 mol/L NaCl, and provides
excellent preservation of tissue structure and antigenic-described [19]. Twenty-four hour urinary protein sam-
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ity. For plasminogen activator inhibitor-1 (PAI-1) stain- was 2.5  0.3-fold that of control animals (N  7, P 
ing, 3.7% formaldehyde in 0.1 mol/L phosphate buffered 0.01; Fig. 2A) Immunohistochemical localization indicated
saline (PBS; pH 7.2) was used for perfusion and fixation; increased COX-2 expression in macula densa and sur-
for TGF- and fibronectin immunostaining, FPAS, which rounding cTALH (Fig. 2B). SC58236 decreased COX-2
contains 3.7% formaldehyde, 0.011 mol/L sodium metap- expression to 1.3  0.1-fold control (N  7, P  0.01;
eriodate, 0.04 mol/L sodium phosphate, 1% acetic acid Fig. 2A).
and 0.1 mol/L NaCl, was used. The fixed kidneys were Expression of other factors implicated in glomerular
dehydrated through a graded series of ethanols, embed- and tubulointerstitial injury was also determined. At the
ded in paraffin, sectioned at 4m thickness and mounted end of six weeks, fibronectin, TGF-, PAI-1, and VEGF
on glass slides. COX-2 immunoreaction was localized with
were all elevated in the diabetic-hypertensive model, andCOX-2 anti-serum diluted to 2.5 ng/mL. The first anti-
these increases were significantly blunted in the diabeticbody was localized using Vectastain ABC-Elite (Vector,
animals receiving SC58236 (diabetic vs. treated: fibro-Burlingame, CA, USA) with diaminobenzidine as the
nectin, 2.4  0.3 to 1.3  0.1-fold control; TGF-, 2.1 chromogen, followed by a light counterstain with tolu-
0.2 vs. 1.3  0.2-fold control; PAI-1, 3.2  0.5 vs. 1.7 idine blue.
0.2-fold control; VEGF, 2.0  0.2 vs. 1.2  0.2-fold con-
Statistical analysis trol; N  7, P  0.05; Fig. 3). Immunohistochemical
analysis confirmed increased fibronectin expression inAll values are presented as mean  SEM. Analysis
the mesangial and cortical tubulointerstitial areas in theof variance (ANOVA) and Bonferroni t tests were used
for statistical analysis, and differences were considered diabetic animals, with less expression in the SC58236-
significant when P  0.05. treated animals (Fig. 4). Similarly, TGF- expression
was increased in both compartments in the diabetic ani-
mals and increased expression was blunted in SC58236-RESULTS
treated rats. PAI-1 expression was very low in controlAs indicated in Figure 1A, in both experimental
animals; there was increased expression in scattered glo-groups, plasma glucose was maintained in the range of
meruli and dramatically increased expression in the tu-200 to 300 mg/dL, and there were no significant differ-
bulointerstitial compartment, with decreased expressionences between the two groups at any time point. The
in SC58236-treated animals. Similarly, VEGF expressionsystolic blood pressure was elevated in both experimen-
was increased in tubular and vascular compartments, andtal groups within one week (control, 109  8 mm Hg;
SC58236-treatment reduced the extent of expression.diabetic, 139  6 mm Hg; treated, 154  10 mm Hg)
Both the untreated and treated diabetic animals devel-and remained elevated until sacrifice at six weeks (con-
oped progressive proteinuria, but the rate of increase introl, 108  2 mm Hg; diabetic, 158  4 mm Hg; treated,
the SC58236-treated animals was significantly blunted156  7 mm Hg; N  7 to 8). There were no significant
differences in BP in the untreated and SC58236-treated (proteinuria at 6 weeks in untreated vs. SC58236-treated
animals (Fig. 1B). Both experimental groups had blunted rats, 149  8 vs. 92  8 mg/24 h; N  7, P  0.01; Fig.
increases in body weight compared to the control ani- 5A). For the mesangial sclerosis index, 286 glomeruli
mals, but again there were no significant differences be- were evaluated and scored in the control animal group,
tween the growth rates of the treated and untreated 94% of which showed a mesangial sclerosis index score
groups at six weeks: control, 362.8  4.7 g; diabetic, of 0 and 6% had mild increases in mesangial matrix
222.7  18.8 g; treated, 243.7  16.4 g (P  0.01 vs. (index score of 1; mean score of 0.06 0.01). No tubulo-
control; N  7 to 8; Fig. 1C). However, the left kidney interstitial fibrosis was seen in the control animals. Three
of SC58236 treated rat was less enlarged at the end of hundred glomeruli were scored in the diabetic group:
six weeks (diabetic, 2.9  0.2 g; treated, 2.5  0.1 g; P  73% of glomeruli showed a mesangial sclerosis index
0.05, N 7), although kidneys in both groups were larger
score of 3, 22% showed a sclerosis index score of 2, 2%than the controls (control, 1.5  0.1 g; N  7 to 8, P 
had an index score of 4, and 3% an index score of 00.01; Fig. 1D). At six weeks, serum creatinine was 0.6 
(mean score of 2.7  0.04). There was minimal focal0.1 mg/dL in control animals and was elevated to 1.5 
increase in interstitial fibrosis in the diabetic animals. In002 in the untreated diabetics and 1.4  0.03 in the
the treated group receiving SC58236, 40% of the 300treated diabetics (N  4). Serum potassium was not
glomeruli examined exhibited a sclerosis index score offound to be significantly different among the three
0 and 60% had a sclerosis index score of 1 (mean scoregroups (4.1  0.3 in control; 3.6  0.1 in diabetic; 3.8 
of 0.6  0.03; Fig. 5B). No interstitial fibrosis could be0.1 mEq/L in treated; N  4; NS).
seen in this group. Representative glomeruli are indi-At the time of sacrifice (6 weeks), immunoreactive
COX-2 expression in the renal cortex of the diabetic rats cated in Figure 5C.
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Fig. 1. Metabolic parameters in hypertensive-diabetic rats without () or with SC58236 treatment (). (A) Plasma glucose. The animals were
treated as described in the Methods section and plasma glucose was monitored weekly until sacrifice at 6 weeks. (B) Systolic blood pressure.
Systolic BP was measured weekly with tail-cuff microphonic manometer. There were no statistically significant differences between treated and
untreated diabetic animals (N  7–8). (C ) Body weight (**P  0.01). SC58236 treated or untreated group was compared with control (N  7–8).
(D) Kidney weight at 6 weeks (*P  0.05, **P  0.01).
DISCUSSION cending limb of Henle (cTALH). Chronic administration
of a selective COX-2 inhibitor, SC58236, significantly de-The present studies demonstrate that in a model of
creased proteinuria and reduced extracellular matrix de-diabetes with superimposed DOCA/salt hypertension,
position, as indicated by decreases in immunoreactive fi-there was increased expression of immunoreactive COX-2
in the macula densa and surrounding cortical thick as- bronectin expression and in mesangial matrix expansion.
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Fig. 2. The COX-2 selective inhibitor, SC58236, decreased immunoreactive COX-2 expression in renal cortex of the hypertensive-diabetic rats.
(A ) At the time of sacrifice (6 weeks), immunoreactive COX-2 expression in the renal cortex was determined by immunoblotting (**P  0.01,
compared with the indicated group; N  7). Insert. Representative experiment: (1) control; (2) untreated hypertensive-diabetic rats; (3) SC58236
treated hypertensive-diabetic rats (**P 0.01). (B) Immunohistochemical localization indicated increased irCOX-2 in macula densa and associated
cTALH of untreated diabetic animals and decreased expression in the SC58236-treated animals.
is evidence for association or overlap of the genetics ofIn addition, SC58236 administration reduced expression
diabetic nephropathy and essential hypertension. Theof TGF-, PAI-1 and VEGF in the kidneys of the dia-
predisposition to essential hypertension in type I diabe-betic hypertensive animals. Therefore, chronic treatment
tes is associated with the development of diabetic ne-with a highly selective COX-2 inhibitor decreased the
phropathy [21]. In type II diabetes, there is increasedexpression of proposed mediators of glomerular and tu-
prevalence of hypertension, which often precedes devel-bulointerstitial injury, and also decreased development
opment of overt diabetes. Studies in Pima Indians haveof functional and structural glomerular abnormalities in
indicated that the level of blood pressure at the time ofresponse to moderately controlled diabetes with super-
onset of diabetes is associated with subsequent develop-imposed hypertension.
ment of nephropathy [22]. Furthermore, in humans withThese studies utilized an experimental model in which
type I and type II diabetes, hypertension has been impli-DOCA/hypertension was superimposed upon moder-
cated as a risk factor for progression of preexistent ne-ately controlled diabetes. Although this model of hyper-
tension is able to self-induce glomerular injury [20], there phropathy.
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Fig. 3. SC58236 treatment reverses up-regulation of renal cortical markers of injury in the diabetic-hypertensive model. At the time of sacrifice
(6 weeks), immunoreactive protein expression in the renal cortex was quantified: (1) control; (2) untreated hypertensive-diabetic rats; (3) SC58236
treated hypertensive-diabetic rats. (A ) Fibronectin, (B ) TGF-; (C ) PAI-1; (D ) VEGF. *P  0.05, **P  0.01, compared with the indicated
group (N  7).
In experimental diabetes, superimposition of hyper- injury. In the present studies, the hypertensive diabetic
rats had significant increases in mesangial area by sixtension increased glomerular injury [23], and a recent
study has demonstrated that glomerular up-regulation weeks, although there was minimal if any involvement
of capillary loops. Therefore, this model provided theof TGF- receptor expression in early experimental dia-
betes required superimposed hypertension [24]. Since ability to examine effect of intervention upon early
nephropathic changes.previous micropuncture studies by Zatz and co-workers
indicated that increases in glomerular capillary pressure In this model of diabetes with hypertension, immuno-
reactive renal cortical COX-2 expression was signifi-are important for development of diabetic glomerular
injury [25, 26], and the model of DOCA/salt hyperten- cantly increased at six weeks, especially in the macula
densa and surrounding cTALH cells, and this increasedsion also increases glomerular capillary pressure [20, 27],
we utilized this model in an attempt to accelerate diabetic expression was significantly blunted by chronic treat-
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Fig. 4. Immunohistochemical analysis of markers of injury. Immunohistochemical analysis (10) at time of sacrifice (6 weeks) of fibronectin (A),
TGF-; (B) PAI-1 (C ) and VEGF (D).
ment with a highly selective COX-2 inhibitor. In agree- induced diabetes and poor glycemic control [28]. It is of
interest that there was up-regulation of COX-2 expres-ment with the current studies, Komers et al have recently
reported increased macula densa/cTALH COX-2 immu- sion in the macula densa and surrounding cTALH in
the current studies, since the animals were presumablynoreactivity in rats with four weeks of streptozotocin-
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Fig. 5. (A) SC58236 treatment blunted progressive proteinuria in diabetic-hypertensive rats. Twenty-four hour proteinuria was monitored weekly
until sacrifice at 6 weeks. Both groups developed progressive proteinuria, but SC58236 treatment significantly blunted the rate of increase (**P 
0.01, N  7). (B and C ) SC58236 decreased mesangial matrix expansion in diabetic-hypertensive rats. (B) Mean mesangial sclerosis index of the
different experimental groups (see text for details; ***P  0.001). (C) Representative glomeruli in (A) control; (B) diabetic; (C) diabetic 
SC58236 (40).
volume expanded secondary to DOCA treatment and alocorticoids to adrenalectomized rats down-regulates
MD/cTALH COX-2 expression [31]. Although we have1% salt in the drinking water. We initially reported that
macula densa/cTALH COX-2 expression increases in not yet determined the signal(s) mediating increased
COX-2 expression in this diabetic model, it is worthresponse to salt depletion [13], and we and others have
subsequently reported that decreased extracellular chlo- noting that recent studies have indicated that glomerular
hyperfiltration in diabetic rats occurs as compensationride mediates the increase in macula densa (MD)/
cTALH expression [29, 30]. Furthermore, we also pre- for increased proximal fractional reabsorption and a de-
crease in electrolyte load to the distal nephron, resultingviously reported that physiologic replacement of miner-
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in resetting of tubuloglomerular feedback to a higher sin- to control levels [28]. Cyclooxygenase-derived arachi-
gle nephron glomerular filtration rate (SNGFR) [32, 33]. donic acid metabolites are mediators of altered renal
There have been numerous studies that indicate that hemodynamic function in response to inflammatory re-
the growth factor/cytokine, TGF-, is an important medi- nal diseases [57], and a number of studies have indicated
ator of diabetic nephropathy [24, 34–37]. TGF- has that cyclooxygenase metabolites may mediate altered
been implicated in both glomerular matrix accumulation renal function in models of renal ablation [58]. In addi-
and tubulointerstitial fibrosis [38]. In the diabetic hyper- tion, NSAIDs have been reported to be effective in re-
tensive model employed in the present studies, increased ducing proteinuria in patients with refractory nephrotic
immunoreactive TGF- expression was detected in both syndrome [59–62]. Defective autoregulation of renal
glomeruli and tubules. Although in vitro studies have blood flow due to decreased myogenic tone of the affer-
indicated that hyperglycemia per se may be a mediator ent arteriole is seen in experimental diabetes as well as
of increased TGF- expression by kidney cells [38–40], with subtotal ablation or excessive dietary protein and
in the present studies, expression of TGF- was blunted is corrected by inhibition of cyclooxygenase activity
by chronic treatment with the COX-2 inhibitor even [63–65]. In these hyperfiltering states, tubuloglomerular
though the degree of hyperglycemia was identical to the feedback (TGF) is reset at a higher distal tubular flow
untreated animals. rate [66–68]. Such a resetting dictates that afferent arteri-
In both experimental and human diabetic kidney dis- olar vasodilatation will be maintained in the face of in-
ease, there is increased production of extracellular ma- creased distal solute delivery. Recent studies by Ishihara
trix components, including fibronectin, type IV collagen et al have suggested that COX-2-mediated prostanoids
and laminin [41–44]. Of note, Ziyadeh et al found that may be essential for arteriolar vasodilation [69].
treatment with TGF- antibody normalized renal fibro- The prostanoids involved have not yet been com-
nectin expression in db/db mice, a genetic model of mu- pletely characterized. Although vasodilatory prostanoids
rine diabetes [36]. PAI-1 expression is increased also in are presumably involved in mediation of the altered re-
diabetic nephropathy [45, 46]. Although the factor(s) nal hemodynamics, thromboxane has been shown to
mediating this up-regulation have not yet been com- stimulate mesangial cell matrix production by both TGF-
pletely determined, there is evidence that TGF- may
–dependent and TGF-–independent pathways [70, 71].
up-regulate PA-1 expression [47]. In diabetic kidney,
Some but not all studies have demonstrated that throm-
increased VEGF expression has been previously re-
boxane synthase inhibitors retarded progression of glo-ported in glomeruli, medullary rays and papillae [48],
merulosclerosis, with decreased proteinuria and glomer-and cell culture studies have suggested that TGF- also
ulosclerosis in rats with remnant kidneys and in diabeticmay mediate VEGF expression [49], but in the db/db
nephropathy [72–78].model of mouse diabetes, treatment with a blocking
Thus, in a model of diabetes with superimposed hyper-TGF- antibody did not inhibit the observed up-regu-
tension, administration of a highly selective COX-2 in-lated expression of VEGF [36].
hibitor decreased expression of agonists postulated toFollowing unilateral nephrectomy, there is compensa-
mediate progression of diabetic renal injury and retardedtory hypertrophy, with an approximately 60% increase
functional and structural renal injury. The mechanism(s)in size of the remaining kidney. There also is renal hyper-
underlying this renoprotective effect has not yet beentrophy in poorly controlled diabetes, with increases in
determined, but it is of interest that the same degree ofboth whole kidney weight and glomerular volume [50].
hyperglycemia and hypertension were present in bothAlthough the mechanisms for diabetic hypertrophy have
vehicle-treated and SC58236-treated animals, indicatingnot yet been completely elucidated, there is evidence
that the reduced expression in the treated group was notthat TGF- expression in both glomeruli and tubules
the result of alterations in systemic blood pressure ormay be involved [51–53]. Of interest in the present stud-
the diabetic milieu.ies, renal hypertrophy was partially but significantly
blunted with treatment with the COX-2 inhibitor.
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